Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 222Liver Neoplasms 68Neoplasms 18Pancreatic Neoplasms 16Neoplasm Metastasis 14Colorectal Neoplasms 12Rectal Neoplasms 8Stomach Neoplasms 7Colonic Neoplasms 7Carcinoma, Renal Cell 6Carcinoma 6Liver Diseases 5Gallbladder Neoplasms 5Breast Neoplasms 5Digestive System Neoplasms 4Bile Duct Neoplasms 4Prostatic Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Melanoma 2Hepatoblastoma 2Hepatitis C 2Hepatitis B 2Hematologic Neoplasms 2Glioblastoma 2

Interventions

carotuximab 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Liver Cell × Sorafenib × Gastrointestinal × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡